PSPeptides manufactures all GHK-Cu peptide domestically, reducing transit time and exposure to temperature variations that can degrade peptide integrity before it reaches your laboratory
It also does not establish pharmacological safety, human bioavailability or clinical effectiveness
In CMSs words, beneficiaries with those diagnoses are ineligible to receive them through the Medicare GLP-1 Bridge, even if they otherwise meet the Medicare GLP-1 Bridge clinical criteria. The distinction that catches people: pre-diabetes still qualifies you for the Bridge, but type 2 diabetes routes you to standard Part D
The choice between them often depends on an individuals medical history, treatment goals, and how their body responds to the different hormone pathways targeted by these drugs
This is where the product either stands on solid ground or falls apart, depending on the evidence